Neurological
Refine Search
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Trintellix (vortioxetine) for the treatment of depression and depressed state, according to the drug’s developers, Danish CNS specialist Lundbeck and its partner Japan’s Takeda Pharmaceuticals
. 20 September 2019
Pharmaceutical
US drugmaker Purdue Pharma has filed for bankruptcy and announced an agreement in principle on a framework for settling the opioid litigation facing the company in the USA. 17 September 2019
Biotechnology
Danish CNS specialist Lundbeck saw its share rise by 5.7% to 249.90 Danish kroner after it revealed plans to acquire a significant migraine asset with the takeover of US drug developer Alder BioPharmaceuticals. 16 September 2019
Biotechnology
US biotech major Biogen] has completed registration of Spinraza (nusinersen), one of the world’s most expensive drugs, for the treatment of spinal muscular atrophy (SMA) in Russia, according to the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 16 September 2019
Pharmaceutical
Denmark’s Novo Nordisk was in the news last week, first with the launch of its own generic NovoLog, aiming to help provide cheaper insulin in the USA, and second with a mixed report from US cost-effectiveness watchdog the ICER evaluating the diabetes care giant’s oral semaglutide. On the research front, adding to the litany of Alzheimer disease failures, were disappointing Phase III results for Neurotrope’s bryostatin-1, but Acadia Pharmaceuticals pleased investors with positive trial readings for its dementia drug Nuplazid. Also attracting attention was Sanofi’s decision to terminate its four-year collaboration with Lexicon Pharma on the diabetes drug Zynquista. 15 September 2019
Pharmaceutical
In what may be viewed as another nail in the coffin of the once-dominant “amyloid beta” theory of Alzheimer’s disease, collaborators Biogen and Eisai have announced a Phase III failure for the oral BACE inhibitor elenbecestat. 13 September 2019
Biotechnology
As World Alzheimer’s Day 2019 approaches (September 21), with the aim this year of raising global awareness and understanding of the stigma, stereotypes and myths that surround a dementia diagnosis; Alessio Brunello, pharma analyst at GlobalData, comments: ‘‘Its timely to reflect that no new drug for Alzheimer’s disease AD) has been approved in the past 17 years, despite more than 400 clinical trials and billions of dollars being spent in an attempt to tackle the disease and address unmet needs.’’ 13 September 2019
Pharmaceutical
With the aim of curbing diversion and misuse, the US Drug Enforcement Administration (DEA) is proposing to reduce the amount of five Schedule II opioid controlled substances that can be manufactured in the United States next year compared with 2019, per the Notice of Proposed Rulemaking being published in the Federal Register and available for public inspection here. 12 September 2019
Biotechnology
Roche today presented full pivotal Phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease. 12 September 2019
Pharmaceutical
According to media reports, privately-owned Purdue Pharma has reached a preliminary proposed settlement with multiple state, local and tribal governments that accuse the company of helping to drive the opioid crisis. But many attorney generals are opposing it and say the fight is not over. 12 September 2019
Biotechnology
A survey from industry analyst Spherix Global Insights suggests that more people may be using anti-calcitonin gene-related peptide (CGRP) therapies for episodic migraines than had been reported. 11 September 2019
Pharmaceutical
Shares of Canada-based Xenon Pharmaceuticals were down 1.9% at $9.33 by mid-morning today, despite revealing a lucrative licensing deal for its pain drug candidate XEN402. 10 September 2019
Pharmaceutical
A highly-anticipated report from Public Health England (PHE) finds that up to a quarter of adults are being prescribed medication for pain, insomnia or depression. 10 September 2019
Pharmaceutical
Meaning that yet another Alzheimer’s disease investigational therapy is likely biting the dust, USA-based orphan disease specialist Neurotrope saw its shares plunge nearly 80% yesterday, after it announced that its candidate bryostatin-1 had failed in a Phase II study. 10 September 2019
Pharmaceutical
The Russian government has decided to allocate additional funding for the purchases of some vital, imported drugs, which are not produced in the country, amid fears of their potential shortage in the local market, according to recent statements made by an official spokesman of the Russian Ministry of Health as well as some industry’s analysts, reports The Pharma Letter’s local correspondent. 10 September 2019
Pharmaceutical
Mallinckrodt, along with its wholly-owned subsidiaries Mallinckrodt LLC and SpecGx, have reached a settlement in principle with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation (MDL) in the US District Court for the Northern District of Ohio 9 September 2019
Biotechnology
In a bold move to broaden its interests overseas, Japanese drugmaker Sumitomo Dainippon has agreed to pay $3 billion for a chunk of Roivant Sciences’ biopharmaceutical units, plus a 10% share in the rest of the company. 6 September 2019
Pharmaceutical
Ireland-registered drugmaker Mallinckrodt was trading 42% down by lunchtime on Thursday as markets mused over reports of increased risk from litigation relating to the opioid crisis. 5 September 2019
Pharmaceutical
More than $1.8 billion has been released by the US Department of Health and Human Services (HHS) to help combat the opioid crisis in the USA. 5 September 2019
Biotechnology
Around the world, life expectancy continues to increase while birth rates fall, leading to aging populations that are increasingly vulnerable to dementia. 4 September 2019
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November meeting, notable among which was a reversal of a previous rejection of Alzheimer’s drug Leqembi (lecanemab). 15 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze